RxDoctor Payments Data

Paul Antal, MD

Family Medicine · Manistee, MINPI 1295845469

Payments from drug & device makers

$967in general payments, 2019–2025

Across 79 payments — averaging $12.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$187
  • Novo Nordisk$161
  • Pfizer$107
  • AbbVie$94
  • Amgen$64
  • Sunovion Pharmaceuticals Inc.$62
  • plus $290 from 10 others

What the payments were for

  • Food & beverage$94798%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$967 in reported general payments places this provider in the 70th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$140,639
Medicare patients
153
Services billed
2,761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban137$147,957
JardianceEmpagliflozin62$89,332
Trelegy ElliptaFluticasone/Umeclidin/Vilanter87$81,642
OzempicSemaglutide50$62,638
XareltoRivaroxaban35$49,324
MounjaroTirzepatide37$46,407
JanuviaSitagliptin Phosphate21$32,085
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog28$23,313
TrulicityDulaglutide12$20,568
Tresiba Flextouch U-200Insulin Degludec22$18,326
FarxigaDapagliflozin Propanediol11$17,928
MyrbetriqMirabegron11$12,250
ElmironPentosan Polysulfate Sodium12$11,665
Breo ElliptaFluticasone/Vilanterol11$8,455
Valsartan173$8,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$107$147,957137 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$50$92,441109 claims
Boehringer IngelheimJardiance$11$89,33262 claims
Lilly USA, LLCMounjaro, Trulicity$30$66,97449 claims
Novo NordiskOzempic$161$62,63850 claims
Johnson & JohnsonXarelto$34$49,32435 claims
MerckJanuvia$25$32,08521 claims
AstraZenecaFarxiga$187$17,92811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Manistee

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →